AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6463312
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of methylphenidate (MPD)
Trial: 6463312
Drug: Night after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Night after 20 mg of methylphenidate (MPD) (N3)
Trial: 23385795
Drug: Topical moxifloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical moxifloxacin
Trial: 30652764
Drug: Topical azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical azithromycin
Trial: 29951531
Drug: Norepinephrine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 5 μg/kg/h
Trial: 29951531
Drug: Norepinephrine 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 10 μg/kg/h
Trial: 29951531
Drug: Norepinephrine 15
RxNorm normalized name: norepinephrine 0.15 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine 15 μg/kg/h
Trial: 20736233
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIA group) with ropivacaine 150 mg and epinephrine 0.5 mg, ketorolac 30 mg, and morphine 5 mg
Trial: 20736233
Drug: Local infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local infiltration analgesia (LIAiv group) with ropivacaine 150 mg and epinephrine 0.5 mg, ketorolac 30 mg, and morphine 5 mg given intravenously
Trial: 10469687
Drug: Ganirelix (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganirelix (1.0 or 2.0 mg) administered once daily from stimulation day 6 onwards
Trial: 10469687
Drug: Ganirelix (0.0625,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganirelix (0.0625, 0.125, 0.25, 0.5, 1.0 or 2.0 mg) administered during IVF cycles
Trial: 31202686
Drug: Non-pharmacological interventions
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-pharmacological interventions targeting light exposure, fixed meal times, caffeine intake, and exercise; specific details on dosage and duration not provided.
Trial: 28157726
Drug: β-Alanine (BA)
RxNorm normalized name: Alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-Alanine (BA) supplementation 6.4 g·d
Trial: 26081010
Drug: Immediate face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate face-to-face cognitive behavioral therapy (FtF-CBT)
Trial: 26081010
Drug: Stepped Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped Care treatment model (Psychoeducation, Internet-delivered CBT, and FtF-CBT)
Trial: 26081010
Drug: Stepped Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stepped Care treatment model
Trial: 24083670
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cells (MSCs) administered intravenously after ex vivo culture expansion with autologous ischemic serum
Trial: 11359590
Drug: Test 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test 2: Detection of endtidal CO2 in the oral cavity
Trial: 2843305
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (4 mg)
Trial: 30574860
Drug: Enteral bovine
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enteral bovine lactoferrin (150 mg/kg/day; maximum 300 mg/day)
Trial: 30574860
Drug: Sucrose placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose placebo (same dose)
Trial: 25843533
Drug: Collagenase clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase clostridium histolyticum (CCH) 0.58 mg/0.20 mL injected into palpable cord
Trial: 21030144
Drug: Duloxetine 80mg
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duloxetine 80mg daily for 3 months
Trial: 20126853
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone every three weeks (HR group)
Trial: 20126853
Drug: Oral vitamins
RxNorm normalized name: vitamin A Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamins daily (HV and CV groups)
Trial: 18046974
Drug: Zofenopril 30
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 30 mg od (up-titrated to 60 mg od after 4 weeks in non-responders)
Trial: 18046974
Drug: Enalapril 20
RxNorm normalized name: enalapril 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 20 mg od (up-titrated to 40 mg od after 4 weeks in non-responders)
Trial: 14762880
Drug: Concurrent chemoirradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoirradiation with cisplatin 100 mg/m2 on days 1, 22, and 43 of radiotherapy, followed by adjuvant chemotherapy with ifosfamide 1.4 g/m2, 5-fluorouracil 450 mg/m2, and leucovorin 20 mg/m2 daily for 5 days, repeated every 3 weeks for three cycles
Trial: 14762880
Drug: Concurrent chemoirradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoirradiation with cisplatin followed by adjuvant chemotherapy
Trial: 14762880
Drug: Concurrent chemoirradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoirradiation with cisplatin
Trial: 11683693
Drug: OAAz (amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAAz (amoxicillin 1000 mg b.d. and azithromycin 500 mg on day 1 and 250 mg on days 2-5)
Trial: 11683693
Drug: OCM (clarithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OCM (clarithromycin 250 mg b.d. and metronidazole 500 mg b.d.)
Trial: 11683693
Drug: OBC (bacampicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OBC (bacampicillin 1200 mg b.d. and clarithromycin 500 mg b.d.)
Trial: 11683693
Drug: OAC (omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC (omeprazole 20 mg b.d., amoxicillin 1000 mg b.d., and clarithromycin 500 mg b.d.)
Trial: 9215782
Drug: Accelerated hyperfractionation
RxNorm normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated hyperfractionation (AHF) - 0.89 Gy x 3 fractions/day; total dose 61.4 Gy
Trial: 2168123
Drug: Oat-bran cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat-bran cereal diet (25 g oat bran/d)
Trial: 704919
Drug: 11-Methyl 16,16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 11-Methyl 16,16 Dimethyl Prostaglandin E2 (TM-PGE) administered orally at dosages of 2.5, 5, 7.5, and 10 microgram/kg
Trial: 31314952
Drug: Nerve Growth
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nerve Growth Factor (NGF) injections (1 µg, 4 cm interval)
Trial: 31314952
Drug: Control injections
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control injections (isotonic-saline)
Trial: 28716283
Drug: Dalfampridine extended
RxNorm normalized name: Dalfampridine Extended-Release Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalfampridine extended release (D-ER) 10mg tablets twice daily
Trial: 25533024
Drug: Sapropterin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin therapy
Trial: 18254805
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment based on silymarin/methylsulfonylmethane (S‐MSM) for 1 month
Trial: 10807760
Drug: Oral ethinyl
RxNorm normalized name: ethinyl estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ethinyl estradiol plus cyproterone acetate (CA)
Trial: 10807760
Drug: Transdermal 17beta-estradiol
RxNorm normalized name: Estradiol-17beta
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17beta-estradiol plus CA
Trial: 10807760
Drug: Oral CA
RxNorm normalized name: coral calx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral CA alone
Trial: 10807760
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone esters in transsexual females
Trial: 10807760
Drug: Oral ethinyl
RxNorm normalized name: ethinyl estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ethinyl estradiol plus CA
Trial: 10807760
Drug: Parenteral testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parenteral testosterone in females
Trial: 9500129
Drug: Somnium (lorazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somnium (lorazepam 1 mg + diphenhydramine 25 mg)
Trial: 9234051
Drug: lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam (1 mg)
Trial: 16368472
Drug: Conventional HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional HRT (estradiol (E2) 2 mg/d during 12 days, E2 2 mg/d plus 1 mg/d of norethisterone acetate (NETA) during 10 days, E2 1 mg/d for 6 days)
Trial: 16368472
Drug: Long-cycle HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-cycle HRT (two cycles with E2 2 mg/d during 28 days, followed by one cycle of conventional HRT and repeated every 3 months)
Trial: 12830471
Drug: Ribavirin monotherapy
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin monotherapy (1,000 mg daily, adapted to hemoglobin level)
Trial: 12830471
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ribavirin therapy)
Trial: 31174846
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg scopolamine
Trial: 3149771
Drug: 1.2 mg
RxNorm normalized name: RNA 1.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg scopolamine
Trial: 10953765
Drug: 1.8 mg
RxNorm normalized name: menthol 1.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.8 mg scopolamine
Trial: 10953765
Drug: 0.75 mg
RxNorm normalized name: propinox 0.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg subcutaneous physostigmine
Trial: 7890463
Drug: Reduced Volume
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced Volume Taper (RVT)
Trial: 7890463
Drug: Rest Only
RxNorm normalized name: Rest Simply
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rest Only Taper (ROT)
Trial: 29229613
Drug: Acupuncture plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture plus auricular acupuncture (combination treatment)
Trial: 26998845
Drug: Primary debulking
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary debulking surgery (PDS) followed by systemic adjuvant chemotherapy (arm A)
Trial: 26998845
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) (arm B)
Trial: 24363029
Drug: Adalimumab 160/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab 160/80 (160 mg at weeks 0/2, then 40 mg every other week)
Trial: 20007996
Drug: Filgrastim (FIL)
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim (FIL) at a daily dose of 5 mug/kg
Trial: 20007996
Drug: Pegfilgrastim (PEG)
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim (PEG) at a single fixed dose of 6 mg
Trial: 10799425
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO) supplementation (500 mg daily for nine weeks)
Trial: 6667282
Drug: Beta-blockade (propanolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockade (propanolol 160 mg/day)
Trial: 8842111
Drug: Mefloquine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (15 mg/kg)
Trial: 31779926
Drug: Other medications
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other medications
Trial: 22269152
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg plus Fenofibrate 160 mg
Trial: 20303247
Drug: Combination therapies
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapies including salmeterol qd or bid
Trial: 17710485
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of prednisolone intravenously for 3 days (steroid group)
Trial: 9452942
Drug: Donepezil (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (up to 10 mg/day)
Trial: 8578163
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg every morning for 14 days) + Amoxicillin (500 mg oral suspension four times daily for 11 days)
Trial: 8578163
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg every morning for 14 days)
Trial: 8578163
Drug: Lansoprazole +
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole + Amoxicillin
Trial: 31768768
Drug: Unfocused extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfocused extracorporeal shockwave therapy (3,000 electrohydraulic-generated shockwaves at 0.3 mJ/mm2)
Trial: 26414670
Drug: Depression Medication
RxNorm normalized name: Nerve depressants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depression Medication Choice (DMC)
Trial: 8314512
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of mebeverine hydrochloride into the sigmoid colon
Trial: 2894246
Drug: Nipradilol (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipradilol (9 mg)
Trial: 27769675
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL liposomal bupivacaine (13.3 mg/mL)
Trial: 27769675
Drug: 4 mL
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mL 0.5% bupivacaine with 1:200,000 epinephrine
Trial: 25439367
Drug: SMART (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SMART (single budesonide‐formoterol inhaler as maintenance and reliever therapy)
Trial: 25439367
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (fixed‐dose regimen with salbutamol as reliever)
Trial: 22444829
Drug: Ranibizumab monotherapy
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab monotherapy (0.5 mg, administered monthly)
Trial: 22444829
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (verteporfin SF or RF)
Trial: 20651204
Drug: Group A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: 300 mg I/mL, 50 mL contrast material followed by a 20-mL saline bolus at 3.0 mL/s
Trial: 20651204
Drug: Group B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B: 300 mg I/mL, 100 mL contrast material at 3.0 mL/s
Trial: 29319646
Drug: Telenursing (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenursing (weekly phone calls for 12 weeks)
Trial: 24954166
Drug: Morphine (10mg)
RxNorm normalized name: morphine 10 MG/ML
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (10mg)
Trial: 24075453
Drug: Canakinumab 5
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 5 mg
Trial: 24075453
Drug: Canakinumab 15
RxNorm normalized name: canakinumab 150 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canakinumab 15 mg
Trial: 10088139
Drug: Pindolol 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol 7.5 mg/day with TSD
Trial: 7025683
Drug: Combined multidrug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined multidrug chemotherapy
Trial: 31819377
Drug: Combined 25‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 25‐G pars plana vitrectomy (PPV) with intravitreal dexamethasone implant (DXI)
Trial: 31819377
Drug: Standard 25‐G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 25‐G PPV with ERM peeling only (control group)
Trial: 15200998
Drug: Chemotherapy (C),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (C), 192 patients, three 3-weekly cycles of cisplatin/vindesine, mitomycin/ifosfamide/cisplatin, mitomycin/vinblastine/cisplatin or vinorelbine/cisplatin.
Trial: 15200998
Drug: No chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No chemotherapy (NoC), 189 patients.
Trial: 9555596
Drug: Risperidone (RIS)
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone (RIS) 6.9 mg
Trial: 9555596
Drug: Haloperidol and
RxNorm normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Haloperidol and Amitriptyline (HAL/AMI) 9 mg and 180 mg respectively
Trial: 2839442
Drug: Conventional daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional daily radiation (5 x W) - 5 daily fractions of 2 Gy each to a total dose of 60 Gy in 6 weeks, protecting the spinal cord at 45 Gy.
Trial: 2839442
Drug: Once‐a‐week radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once‐a‐week radiation (1 x W) - one weekly fraction of 5 Gy each to a total tumor dose of 60 Gy in 12 weeks, protecting the spinal cord at 30 Gy.
Trial: 31763943
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B 25 mg IV-RLP
Trial: 31763943
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B 50 mg IV-RLP
Trial: 31763943
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B 300 mg IV-RLP
Trial: 25403578
Drug: FOLFOX4 (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 (oxaliplatin 85 mg/m²)
Trial: 25403578
Drug: FOLFOX7 (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX7 (oxaliplatin 130 mg/m²) followed by FOLFIRI (irinotecan 180 mg/m²)
Trial: 23598459
Drug: Diuretic adjustment
RxNorm normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic adjustment according to the AAD (algorithm de ajuste de diurético)
Trial: 19514695
Drug: High-dose beta-lactam/beta-lactamase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose beta-lactam/beta-lactamase inhibitor or second-/third-generation cephalosporin with azithromycin
Trial: 19514695
Drug: Broad-spectrum antibiotics
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotics for hospitalized patients
Trial: 16675478
Drug: Uracil-tegafur (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uracil-tegafur (400 mg/m2 tegafur per day) for one year
Trial: 16675478
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (surgery-alone group)
Trial: 14722640
Drug: ICG‐PDR(0.5) with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG‐PDR(0.5) with dosage 0.5 mg/kg
Trial: 14722640
Drug: ICG‐PDR(0.25) with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG‐PDR(0.25) with dosage 0.25 mg/kg
Trial: 11803864
Drug: Melbrosia treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melbrosia treatment group
Trial: 9557910
Drug: 0.5 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg(‐1) ephedrine intramuscularly
Trial: 9557910
Drug: 0.25 mg.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg.kg(‐1) propofol intravenously
Trial: 9557910
Drug: 0.1 ml.kg(‐1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml.kg(‐1) normal saline intravenously
Trial: 7849542
Drug: Fluoride therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride therapy (mean, 23 mg elemental F daily for approximately 18 months)
Trial: 7849542
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (38 osteoporotic females not receiving fluoride therapy)
Trial: 11148800
Drug: Fluoride therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride therapy
Trial: 3170393
Drug: amikacin 15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amikacin 15.0 mg/kg administered in a single daily dose
Trial: 3170393
Drug: amikacin 11.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amikacin 11.0 mg/kg administered in a single daily dose
Trial: 3170393
Drug: amikacin 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amikacin 7.5 mg/kg administered twice daily